Physician profile
Robert P Green
NPI 1528075801
$3,368.94
in general payments reported to CMS, 2019-2025
21 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $170 · 2020: $247 · 2021: $204 · 2022: $787 · 2023: $189 · 2024: $997 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,943 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,942.67 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $567.95 | 2022-2025 | Clareon, Centurion, Rocklatan |
| Abbvie INC. | $536.33 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $302.40 | 2020-2024 | Tecnis Simplicity |
| Rxsight INC | $248.87 | 2022-2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb Americas INC. | $244.96 | 2022-2024 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $189.24 | 2020-2021 | |
| Glaukos Corporation | $155.64 | 2024-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished), Photrexa |
| Astellas Pharma US INC | $146.99 | 2023-2024 | Izervay |
| Sight Sciences, INC. | $136.95 | 2025 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $133.78 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $116.86 | 2020-2021 | |
| Genentech USA, INC. | $116.62 | 2019 | |
| Acumed LLC | $106.60 | 2024 | Acumed |
| Sun Pharmaceutical Industries INC. | $102.69 | 2019-2023 | Cequa |
| Biotissue Holdings INC. | $95.04 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $73.75 | 2019-2023 | Tepezza |
| Ocular Therapeutix, INC. | $28.77 | 2025 | Dextenza |
| Dompe US, INC. | $21.49 | 2022 | |
| Rayner Intraocular Lenses Limited | $19.09 | 2024 | Rayone Emv, Rayner Cataract Set 1, Rayone Aspheric |
| Allergan, INC. | $14.92 | 2021 | |
| Lensar, INC. | $10.00 | 2024 | Lensar Laser System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.